Analyst Price Targets — UNH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 17, 2026 12:40 pm | David MacDonald | Truist Financial | $500.00 | $429.39 | TheFly | UnitedHealth price target raised to $500 from $480 at Truist |
| July 17, 2026 11:41 am | — | UBS | $490.00 | $423.38 | TheFly | UnitedHealth price target raised to $490 from $460 at UBS |
| July 17, 2026 10:40 am | — | Morgan Stanley | $529.00 | $423.38 | TheFly | UnitedHealth price target raised to $529 from $468 at Morgan Stanley |
| July 17, 2026 10:26 am | Matthew Gillmor | KeyBanc | $500.00 | $423.38 | TheFly | UnitedHealth price target raised to $500 from $475 at KeyBanc |
| July 16, 2026 4:52 pm | Michael Ha | Robert W. Baird | $453.00 | $429.43 | TheFly | UnitedHealth upgraded to Neutral from Underperform at Baird |
| July 16, 2026 11:57 am | Jessica Tassan | Piper Sandler | $477.00 | $446.72 | StreetInsider | UnitedHealth Group (UNH) PT Raised to $477 at Piper Sandler, 'We would be buyers' |
| July 15, 2026 5:23 pm | — | Piper Sandler | $475.00 | $419.23 | TheFly | UnitedHealth price target raised to $475 from $420 at Piper Sandler |
| July 14, 2026 11:47 am | — | Truist Financial | $480.00 | $429.09 | TheFly | UnitedHealth price target raised to $480 from $440 at Truist |
| July 14, 2026 9:52 am | Matthew Gillmor | KeyBanc | $475.00 | $429.09 | TheFly | UnitedHealth price target raised to $475 from $400 at KeyBanc |
| July 13, 2026 11:08 am | — | Wells Fargo | $485.00 | $424.62 | TheFly | UnitedHealth price target raised to $485 from $397 at Wells Fargo |
Latest News for UNH
On Thursday, July 16, during the broadcast of Mad Money , Jim Cramer pushed back on the market's punishment of several blue-chip companies that just posted strong quarters.
AI spending fears rattled chip stocks all week long. Meanwhile, an insurance company quietly saved the Dow from a worse fate.
The FDA's approval of Merck (NYSE:MRK | MRK Price Prediction) enlicitide decanoate, marketed as Lipfendra, marks the first once-daily oral PCSK9 inhibitor cleared for adults with high LDL cholesterol, including heterozygous familial hypercholesterolemia.
UNH lifts its 2026 outlook as Medicare and Optum improve, while commercial cost pressures delay margin recovery and keep management focused on execution.
UnitedHealth Group Inc. (NYSE:UNH) spent much of its second-quarter earnings call talking about recovering margins, stronger guidance and operational improvements. But there was another message hidden in plain sight.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.